People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Medicenna Therapeutics Corp. | — | Biotechnology | Series A | $23.8M | $82.9M | 2024 |
John Geltosky at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Geltosky on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Elizabeth Williams | 1 | 9 |
| FAHAR MERCHANT | 1 | 3 |
| David Hyman | 1 | 3 |
| Karen Dawes | 1 | 2 |
| Rosemina Merchant | 1 | 2 |
| CHANDRA PANCHAL | 1 | 2 |
| ROSEMINA G. MERCHANT | 1 | 1 |
| John Sampson | 1 | 1 |
| Albert Beraldo | 1 | 1 |
| KAREN G. DAWES | 1 | 1 |
| ALBERT G. BERALDO | 1 | 1 |
| ANDREW G. STRONG | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.